Cardiotoxicity of Chemotherapy Agents

Introduction to Cardiotoxic Agents

• The American Society of Clinical Oncology recommends that the most cardiotoxic drugs are anthracyclines (such as doxorubicin), followed by alkylating agents (such as cyclophosphamide), fluorouracil (5-FU), trastuzumab, and paclitaxel, each with different mechanisms of cardiotoxicity and incidence rates 1, 2

Anthracyclines

• The incidence of anthracycline-induced cardiotoxicity varies depending on the drug and cumulative dose: for doxorubicin, it ranges from 4% to >36% in patients receiving 500-550 mg/m² 1
• Cardiotoxicity is classified as acute (transient decrease in myocardial contractility immediately after infusion, incidence <1%), early-onset chronic (within the first year after treatment, incidence 1.6%-2.1%), and late-onset chronic (up to 10-30 years after the first dose) 2, 3, 4
• Risk factors include high cumulative dose, high single intravenous dose, infusion time <30 minutes, previous radiation therapy, concomitant use of cyclophosphamide/trastuzumab/paclitaxel, female sex, very young or advanced age, and underlying cardiovascular disease 4

Alkylating Agents

• Cyclophosphamide: the incidence of heart failure ranges from 7% to 28%, mainly related to the dose 1

Targeted Molecular Agents

• Trastuzumab: a monoclonal antibody that causes heart failure in 2%-7% of patients; this increases to 27% when used concurrently with anthracyclines 1, 2

Agents Related to Myocardial Ischemia/Thromboembolism

• Fluorouracil (5-FU): the most common cardiotoxic effect is angina-like chest pain, with an incidence of 1% to 68%; ischemic changes on the ECG have been reported in 68% of patients 1, 2
• Paclitaxel: can induce ventricular arrhythmias, bradycardia, atrioventricular conduction blocks, bundle branch block, and cardiac ischemia 1, 2

Other Cardiotoxic Agents

• Mitoxantrone (antraquinone derivative): causes myocarditis and arrhythmias acutely; after 1 year of monotherapy, 3%-4% of patients have a reduced left ventricular ejection fraction 1, 2

Mechanisms of Cardiotoxicity

• Anthracyclines: formation of free radicals and apoptosis of myocardial cells 4
• 5-FU: coronary artery thrombosis, interaction with the coagulation system, vasospasm, and direct toxicity to the myocardium 1
• Trastuzumab: inhibition of critical signaling pathways for cardiomyocyte survival 2

Evaluation and Monitoring

• All patients receiving chemotherapy should have a careful clinical evaluation and assessment of cardiovascular risk factors or comorbidities 5
• Frequent monitoring of vital signs during the infusion of chemotherapeutic agents is recommended, particularly with 5-FU or paclitaxel 5
• ECG and clinical cardiovascular evaluation are useful for detecting signs of cardiomyopathy, conduction disorders, and QT interval before starting therapy with anthracyclines, paclitaxel, or tyrosine kinase inhibitors 3

Special Considerations

• Liposomal doxorubicin shows reduced cardiotoxicity, although at the cost of hand-foot syndrome and other skin toxicities; it may be preferable in selected patients with a high risk of heart failure 1, 4
• The combined use of doxorubicin and paclitaxel is limited by a higher incidence of cardiac toxicity 1

Cardiac Arrest on Day 3 of Chemotherapy: Most Likely Cause

Primary Mechanism: Chemotherapy-Induced Arrhythmias

• The European Society of Cardiology recommends considering arrhythmias as a primary mechanism of cardiac arrest in patients undergoing chemotherapy, due to direct cardiotoxic effects of chemotherapeutic agents on cardiac ion channels and myocardial function 6, 7
• Direct cardiac ion channel effects cause QT prolongation, ventricular tachyarrhythmias, bradycardia, and conduction blocks during or immediately after chemotherapy infusion, with a high incidence in cancer patients 6, 7
• Acute cardiotoxicity manifests as transient decline in myocardial contractility with incidence <1% immediately after infusion, creating an arrhythmogenic substrate 8
• Specific high-risk agents, including anthracyclines, paclitaxel, 5-fluorouracil, arsenic trioxide, and alkylating agents, can trigger life-threatening arrhythmias within days 6, 9, 10

Clinical Approach to This Patient

• The American Heart Association recommends obtaining a 12-lead ECG as soon as possible to detect QT prolongation, conduction blocks, or ischemic changes in patients with cardiac arrest during chemotherapy 11, 9, 10
• Checking electrolytes immediately, such as potassium, magnesium, and calcium, is crucial as chemotherapy-induced imbalances potentiate arrhythmias 11
• Reviewing specific chemotherapy agents administered to identify known arrhythmogenic drugs is essential 6
• Consideration of bedside echocardiography during resuscitation to assess for acute right ventricular dysfunction or global dysfunction is recommended 11

Post-Resuscitation Management Priorities

• Continuous cardiac monitoring for recurrent arrhythmias is essential in patients who have experienced cardiac arrest during chemotherapy 6
• Correcting metabolic derangements aggressively, particularly electrolyte abnormalities that lower arrhythmia threshold, is critical 11
• Avoiding QT-prolonging medications and reassessing chemotherapy regimen with oncology is recommended 6, 7
• Targeted temperature management 32-34°C for 24 hours may be beneficial if the patient remains comatose post-ROSC 11

Critical Pitfalls to Avoid

• Assuming sepsis without fever, leukocytosis, or source is not recommended, as Day 3 is too early for neutropenic sepsis 11
• Overlooking drug-specific risks, such as anthracyclines, paclitaxel, and 5-FU, which have high acute arrhythmia rates, is a critical pitfall 9, 10

Cardiotoxicity of Chemotherapy Agents

Comparative Cardiotoxicity Profile

• 5-Fluorouracil primarily causes coronary vasospasm and myocardial ischemia, not congestive heart failure, with angina-like chest pain and ischemic ECG changes in symptomatic patients, according to the European Society for Medical Oncology 12
• Platinum agents, such as cisplatin, increase the risk of thrombotic events like deep vein thrombosis or pulmonary embolism, but specific cardiotoxicity causing heart failure is rarely reported, as stated by the European Society for Medical Oncology 12
• Methotrexate is not listed among the primary cardiotoxic chemotherapy agents in major guidelines, such as those from the American College of Cardiology, and does not have a recognized association with congestive heart failure 12
• Tamoxifen is primarily associated with thromboembolic complications, not direct cardiotoxicity or heart failure, and is not classified among chemotherapeutic agents with significant cardiomyopathy risk, according to the American Heart Association 12

Clinical Implications for Monitoring

• Baseline echocardiogram with LVEF measurement is mandatory for all patients receiving anthracyclines, especially those with cardiovascular risk factors, age >60 years, previous CVD, or prior mediastinal irradiation, as recommended by the European Society for Medical Oncology 12
• Concurrent use of cyclophosphamide, trastuzumab, or paclitaxel dramatically amplifies cardiotoxicity, with trastuzumab combined with anthracyclines increasing heart failure incidence to 27%, according to the American Society of Clinical Oncology 12

Critical Pitfalls to Avoid

• Do not confuse 5-FU's ischemic cardiotoxicity with the chronic cardiomyopathy caused by anthracyclines, as they have completely different mechanisms, time courses, and management strategies, as warned by the European Society for Medical Oncology 12